Several other research firms also recently weighed in on QURE. HC Wainwright set a $73.00 price target on Uniqure and gave the stock a “buy” rating in a research note on Monday, July 8th. Cantor Fitzgerald increased their price target on Cerner from $75.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, July 8th. Zacks Investment Research upgraded SCHNEIDER ELEC /ADR from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Friday, July 5th. Piper Jaffray Companies set a $80.00 price target on Canopy Growth and gave the stock a “buy” rating in a research note on Friday, April 12th. Finally, Janney Montgomery Scott reiterated a “buy” rating on shares of Uniqure in a research note on Tuesday, June 11th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $78.18.
Shares of Uniqure stock opened at $70.32 on Friday. Uniqure has a 1 year low of $21.98 and a 1 year high of $82.49. The company’s fifty day simple moving average is $71.87. The company has a quick ratio of 9.51, a current ratio of 9.51 and a debt-to-equity ratio of 0.38.
Uniqure (NASDAQ:QURE) last announced its earnings results on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.03). Uniqure had a negative net margin of 1,032.06% and a negative return on equity of 48.90%. The business had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $2.00 million. Equities analysts expect that Uniqure will post -3 earnings per share for the current fiscal year.
In other Uniqure news, CEO Matthew C. Kapusta sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, June 19th. The stock was sold at an average price of $77.45, for a total value of $619,600.00. Following the completion of the transaction, the chief executive officer now owns 409,407 shares in the company, valued at approximately $31,708,572.15. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Christian Klemt sold 1,546 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total value of $88,400.28. Following the completion of the transaction, the insider now owns 54,539 shares of the company’s stock, valued at approximately $3,118,540.02. The disclosure for this sale can be found here. Insiders have sold a total of 23,546 shares of company stock valued at $1,556,820 in the last quarter. 2.91% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Xact Kapitalforvaltning AB purchased a new position in Uniqure in the 2nd quarter worth approximately $328,000. First Citizens Bank & Trust Co. purchased a new position in Uniqure in the 2nd quarter worth approximately $211,000. Sanders Morris Harris LLC purchased a new position in Uniqure in the 2nd quarter worth approximately $3,084,000. FMR LLC increased its stake in Uniqure by 0.8% in the 1st quarter. FMR LLC now owns 3,688,791 shares of the biotechnology company’s stock worth $220,036,000 after purchasing an additional 29,629 shares during the period. Finally, Redmile Group LLC increased its stake in Uniqure by 0.3% in the 1st quarter. Redmile Group LLC now owns 1,307,522 shares of the biotechnology company’s stock worth $77,994,000 after purchasing an additional 4,100 shares during the period. Institutional investors and hedge funds own 60.10% of the company’s stock.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.